C. Mamot

Type de document

Articles (3) Colloques et conférences (2) Recensions (1)

Co-auteur

Date

Source

Mot-clé

survie (5) Survival (5) procès (4) Treatment (4) Patients (4) Bevacizumab (4) Patients (4) thérapie (3) maladie (3) cancer (3) Cancer (3) Therapeutics (3) Manufacturers' agents (3) Impact (3) Commission merchants (3) Cancer (3) Breast (3) Addition (3) maladie (3) toxicité (2) surveillance (2) effet (2) Monitoring (2) Chemotherapy (2) Control (2) Methods (2) Tumors (2) Trials (2) Swiss (2) Prognosis (2)

Documents écrit par C. Mamot (5) | parle de C. Mamot (0)

A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
P. Roth et al. (1 juin 2020)
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
S. Schmid et al. (10 sept. 2019)
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
R. von Moos et al. (2012)
MMP-9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin. A multicenter, single-arm phase II trial (SAKK24/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).
K. Zaman et al. (2010)
hMMP9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin (PLD)
K. Zaman et al. (2010)